Last updated: February 27, 2026
What Is NDC 31722-0066?
NDC 31722-0066 corresponds to Esomeprazole Magnesium Delayed-Release Capsules (brand name: Nexium), indicated primarily for gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and other acid-related conditions. The drug is marketed by AstraZeneca and is available in multiple dosages.
Market Overview
Market Size and Demand
- Global Proton Pump Inhibitors (PPIs) Market: Valued at approximately $14 billion in 2022, projected to grow at a compound annual growth rate (CAGR) of 5%, reaching $22 billion by 2030[1].
- U.S. Market Share: In 2022, the U.S. accounted for roughly 45% of the global acid suppression therapy market, with Nexium holding approximately 8% of the prescriptions among PPIs[2].
- Patient Population: Estimated at 10 million patients in the U.S. alone with chronic GERD, with a steady increase due to aging demographics and rising prevalence of obesity, a known GERD risk factor[3].
Competitive Landscape
- Brand-Name Drugs: Nexium, Protonix, Prilosec, Prevacid.
- Generics: Multiple generics of esomeprazole have entered the market, with increased price competition. As of 2022, generics captured over 60% of prescriptions[4].
- Key Differentiators: Brand recognition, formulation stability, and specific patent protections influence market share and pricing.
Patent and Regulatory Status
- Patent Expiry: The original patents expired by late 2014, leading to an influx of generics.
- Market Exclusivity: Recent formulations (e.g., IV, specialized delivery systems) may retain patent protections until 2030, affecting pricing power.
Pricing Analysis
Current Pricing Landscape
- Brand-Name Price Points: A 30-count supply of Nexium 20 mg capsules retails approximately at $600-$700 in U.S. pharmacies, depending on insurance coverage.
- Generic Pricing: Similar quantities are priced around $50-$70, almost 90% lower than brand name, driven by high generic market penetration.
Reimbursement and Insurance
- Medicare and Medicaid: Reimbursements favor generics significantly; copayments for brand drugs can reach several hundred dollars.
- Commercial Insurance: Negotiated prices often reduce consumer out-of-pocket costs further.
Price Projections
| Year |
Estimated Average Price per 30-count (USD) |
Notes |
| 2023 |
$55 - $75 |
Generic dominance continues, slight inflation |
| 2025 |
$50 - $70 |
Momentum for generics persists, price stabilization anticipated |
| 2030 |
$45 - $65 |
Market saturation, pricing pressure remains dominant |
Note: These projections assume no new patent protections, formulation innovations, or significant market shifts.
Potential Factors Impacting Price Dynamics
- Emerging Formulations: Development of longer-acting formulations or alternative delivery systems could command premium pricing.
- Patent Restorations or Extensions: Minor patent litigations or secondary patents could delay generic entry, supporting higher prices temporarily.
- Market Saturation: A large base of chronic users ensures steady volume, but price sensitivity limits growth opportunities.
Conclusion
The market for NDC 31722-0066 is mature, characterized by high generic penetration and downward pricing pressures. Prices will likely stabilize within current ranges, with slight declines projected over the next five years unless novel formulations or patent protections emerge.
Key Takeaways
- Nexium's global and U.S. markets are sizable but facing intense price competition from generics.
- Current retail prices for brand-name Nexium are approximately $600-$700; generics sell for about $50-$70.
- Price projections suggest minor declines, moving towards $45-$65 per 30-count by 2030.
- Market exclusivity remains limited, with patent expirations pressuring prices.
- Factors like new formulations and patent protections could temporarily influence pricing stratification.
FAQs
Q1: How will patent expirations influence Nexium’s pricing?
A1: Patent expirations facilitate generic entry, leading to significant price reductions and market share shifts towards lower-cost alternatives.
Q2: Are there upcoming formulations that could affect market prices?
A2: While no new formulations have been approved recently for Nexium, innovations such as combination therapies or new delivery methods could create premium pricing opportunities.
Q3: How does insurance coverage impact price projections?
A3: Insurance negotiations favor generics, lowering patient out-of-pocket costs, which sustains high prescription volumes but limits price growth potential for brand-name drugs.
Q4: What are the main risks to the current price projections?
A4: Regulatory changes, patent litigation, or market entry of more effective competing drugs could alter the pricing landscape.
Q5: How does rising prevalence of GERD impact market outlook?
A5: Increasing GERD prevalence sustains demand, but price sensitivity and generic competition mitigate revenue growth for branded formulations.
References
[1] MarketWatch. (2022). Proton pump inhibitors market size and forecast. https://www.marketwatch.com/
[2] IQVIA. (2022). U.S. prescription drug market share data. https://www.iqvia.com/
[3] National Institutes of Health. (2021). GERD epidemiology. https://www.nih.gov/
[4] GoodRx. (2022). Proton pump inhibitor prices and trends. https://www.goodrx.com/
